|
[2] Nguyen KS,Kobayashi S,Costa DB.Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway[J].Clin Lung Cancer,2009,10(4):281-289. |
|
[2]
|
Ulahannan SV,Brahmer JR.Antiangiogenic agents in combination with chemotherapy in patients with advanced non-small cell lung cancer[J].Cancer Invest,2011, 29(4):325-337. |
|
[3] Maemondo M,Inoue A,Kobayashi K,et al.Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR[J].N Engl J Med,2010, 362(25):2380-2388. |
|
[4] Mitsudomi T,Morita S,Yatabe Y, et al.Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor(WJTOG3405):an open label,randomised phase 3 trial[J].Lancet Oncol,2010, 11(2):121-128. |
|
[5] Jnne PA.Challenges of detecting EGFR T790M in gefitinib /erlotinib-resistant tumours[J].Lung Cancer,2008,60 (Suppl2):S3-S9. |
|
[6] Kobayashi S,Boggon TJ,Dayaram T,et al.EGFR mutation and resistance of non-small-cell lung cancer to gefitinib[J].N Engl J Med,2005,352(8):786-792. |
|
[7] Reich NC.STAT3 revs up the powerhouse[J].Sci Signal,2009,2(90):pe61. |
|
[8] Ye MX,Zhao YL,Li Y,et al.Curcumin reverses cis-platin resistance and promotes human lung adenocarcinoma A549 /DDP cell apoptosis through HIF-1 and caspase-3 mechanisms[J].Phytomedicine, 2012, 19(8 /9):779-787. |
|
[9] Petrelli F,Borgonovo K,Cabiddu M,et al.Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated nonsmall-cell lung cancer:a meta-analysis of 13 randomized trials[J].Clin Lung Cancer,2012,13(2):107-114. |
|
[10] Yun CH,Mengwasser KE,Toms AV, et al.The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP[J].Proc Natl Acad Sci USA,2008, 105(6):2070-2075. |
|
[11] Sos ML,Rode HB,Heynck S,et al.Chemogenomic profiling provides insights into the limited activity of irreversible EGFR Inhibitors in tumor cells expressing the T790M EGFR resistance mutation[J].Cancer Res, 2010, 70(3):868-874. |
|
[12] Pao W,Miller VA,Politi KA,et al.Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain[J].PLoS Med,2005,2(3):e73. |
|
[13] Alvarez JV,Greulich H,Sellers WR,et al.Signal transducer and activator of transcription 3 is required for the oncogenic effects of non-small-cell lung cancer-associated mutations of the epidermal growth factor receptor[J].Cancer Res, 2006,66(6):3162-3168. |
|
[14] Choi S,Sano D,Cheung M, et al.Vandetanib inhibits growth of adenoid cystic carcinoma in an orthotopic nude mouse model[J].Clin Cancer Res, 2008, 14(16):5081-5089. |
|
[15] Huang S,Chen M,Shen Y,et al.Inhibition of activated Stat3 reverses drug resistance to chemotherapeutic agents in gastric cancer cells[J].Cancer Lett,2012,315(2):198-205. |
|
[16] Yue P,Zhang X,Paladino D,et al.Hyperactive EGF receptor,Jaks and Stat3 signaling promote enhanced colony-forming ability,motility and migration of cisplatin-resistant ovarian cancer cells[J].Oncogene,2012,31(18):2309-2322. |
|
[17] Zhou J,Ong CN,Hur GM,et al.Inhibition of the JAK-STAT3 pathway by andrographolide enhances chemosensitivity of cancer cells to doxorubicin[J].Biochem Pharmacol,2010,79 (9 ):1242-1250. |
|
[18] Zhang X,Xiao W,Wang L, et al.Deactivation of signal transducer and activator of transcription 3 reverses chemotherapeutics resistance of Leukemia cells via down-regulating P-gp[J].PLoS One,2011,6(6):e20965. |
|
[19] Chiu HC,Chou DL,Huang CT, et al.Suppression of Stat3 activity sensitizes gefitinib-resistant non small cell lung cancer cells[J].Biochem Pharmacol,2011, 81(11):1263-1270. |
|
[20] Chang CJ,Chiang CH, Song WS, et al.Inhibition of phosphorylated STAT3 by cucurbitacin Ⅰ enhances chemoradiosensitivity in medulloblastoma-derived cancer stem cells[J].Childs Nerv Syst,2012, 28(3):363-373. |
点击查看大图
下载:
